CURR - Cure Pharmaceutical launches program examining psychedelics for mental illnesses

Cure Pharmaceutical Holding Corp. (CURR) has begun an initiative that will examine whether the use of psychedelic compounds on its oral film drug delivery platform CUREfilm can treat mental illnesses.The psychedelics included are psilocybin (found in "magic" mushrooms), LSD, and MDMA (ecstasy).Using CUREfilm, Cure intends to maximize the absorption and metabolism of psychedelic actives targeting clinical efficacy of macrodosing and microdosing treatment regimens.The company says a growing body of evidence supports the use of psychedelics in the treatment of depression, PTSD, addiction disorders, obsessive compulsive disorder, and anxiety.Earlier this month, Cure announced two new clinical development programs, one involving an antiviral active pharmaceutical ingredient and the other an anti-seizure API.Cure shares closed Monday down 4.7% to $1.01.

For further details see:

Cure Pharmaceutical launches program examining psychedelics for mental illnesses